Research Article
Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases
Table 3
Univariable analysis of factors associated with improved median overall survival.
| | Univariable | HR (95% CI) | value |
| Age (continuous) | 1.01 (0.98–1.04) | 0.59 |
| Gender | 0.88 | Female | Reference (1.00) | Male | 1.06 (0.50–2.28) |
| ECOG at Y-90 treatment | 0 | Reference (1.00) | | 1 | 1.64 (0.66–4.13) | 0.29 | 2 | 1.25 (0.15–10.42) | 0.84 |
| Tumor differentiation | Well | Reference (1.00) | | Moderate | 2.23 (0.89–5.59) | 0.09 | Poor | 13.29 (1.42–124.41) | 0.02 |
| Ki67 | ≤2 | Reference (1.00) | | 3–20 | 1.95 (0.77–4.79) | 0.16 | >20 | 15.56 (1.50–160.98) | 0.02 | Extrahepatic metastases | 2.14 (0.97–4.71) | 0.06 |
| Hepatic tumor burden | <33% | Reference (1.00) | 0.46 | 33–66% | 2.01 (0.60–6.78) | 0.26 | >66% | 1.32 (0.26–6.60) | 0.74 | Baseline CgA (continuous) | 1.00 | 0.16 | Previous local therapies | 0.79 (0.33–1.88) | 0.59 | Previous SSA | 0.87 (0.39–1.96) | 0.74 | Previous systemic therapies | 1.56 (0.72–3.37) | 0.26 | Previous surgery | 0.42 (0.19–0.91) | 0.03 |
|
|
HR = hazard ratio; ECOG = Eastern Cooperative Oncology Group performance status; CgA = chromogranin A; SSA = somatostatin analogue.
|